[HTML][HTML] Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: a cross-sectional study
A Doi, K Iwata, H Kuroda, T Hasuike, S Nasu… - … epidemiology and global …, 2021 - Elsevier
Objectives Coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has
been affecting many people on earth and our society. Japan is known to have relatively …
been affecting many people on earth and our society. Japan is known to have relatively …
Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies
…, R Yamamoto, S Yoshioka, H Maruoka, S Nasu… - Blood Cancer …, 2023 - nature.com
Patients with hematologic diseases receiving anti-CD20 monoclonal antibodies show a low
seroconversion rate after two doses of mRNA Coronavirus disease-2019 (COVID-19) …
seroconversion rate after two doses of mRNA Coronavirus disease-2019 (COVID-19) …
Sequential breast implant infections due to Campylobacter fetus subsp. fetus
M Nishikubo, S Nasu, H Maruoka, T Kawabata… - Journal of Infection and …, 2021 - Elsevier
Campylobacter jejuni and Campylobacter coli are the leading causes of bacterial intestinal
infections worldwide, while Campylobacter fetus subsp. fetus (C. fetus) has been reported to …
infections worldwide, while Campylobacter fetus subsp. fetus (C. fetus) has been reported to …
Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in allogeneic hematopoietic stem cell transplant recipients: an observational …
M Nishikubo, Y Shimomura, H Maruoka, S Nasu… - Journal of Infection and …, 2023 - Elsevier
Background The effectiveness of mRNA COVID-19 vaccines and the optimal timing of
vaccine administration in allogeneic hematopoietic stem cell transplantation (Allo-HSCT) …
vaccine administration in allogeneic hematopoietic stem cell transplantation (Allo-HSCT) …
[HTML][HTML] Humoral response and safety of the BNT162b2 and mRNA‐1273 COVID‐19 vaccines in patients with haematological diseases treated with anti‐CD20 …
…, Y Shimomura, H Maruoka, S Nasu… - British Journal of …, 2022 - ncbi.nlm.nih.gov
In clinical trials, mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
have shown remarkable efficacy and safety in healthy participants. 1, 2 …
have shown remarkable efficacy and safety in healthy participants. 1, 2 …
Trajectories of the SARS‐CoV‐2 RNA load in patients with hematological malignancy
…, Y Ohyama, H Maruoka, S Nasu… - European Journal of …, 2023 - Wiley Online Library
Objectives The higher risk of prolonged viral shedding in coronavirus disease (COVID‐19)
patients with hematological malignancies (HM) necessitates test‐based de‐isolation …
patients with hematological malignancies (HM) necessitates test‐based de‐isolation …
A descriptive study on the potential transmission of COVID-19 to hospitalized patients from a nursery school affiliated with it
A Doi, K Iwata, T Yamamoto, A Ogura, S Nasu… - Journal of Infection and …, 2024 - Elsevier
Introduction During the epidemic of the Omicron variant of SARS-CoV-2, nosocomial transmissions
from healthcare workers (HCWs) to patients occur frequently. The influence of COVID…
from healthcare workers (HCWs) to patients occur frequently. The influence of COVID…
Sequential cellular and humoral responses after repetitive COVID‐19 vaccination in patients treated with anti‐CD20 antibodies
…, R Yamamoto, H Maruoka, S Nasu… - British Journal of …, 2024 - Wiley Online Library
Patients treated with anti‐CD20 antibodies for haematological disorders have insufficient
immune responses to mRNA COVID‐19 vaccines; however, relevant sequential data are …
immune responses to mRNA COVID‐19 vaccines; however, relevant sequential data are …
A pseudo-outbreak of COVID-19 associated pulmonary aspergillosis: A microbiological investigation of both the patients and the environment
…, T Hasuike, A Ogura, S Nasu… - Journal of Infection …, 2023 - journals.sagepub.com
Background We experienced a pseudo-outbreak of aspergillosis in a newly constructed
COVID-19 ward. Within the first 3 months from the commencement of the ward, six intubated …
COVID-19 ward. Within the first 3 months from the commencement of the ward, six intubated …
[HTML][HTML] A cross-sectional follow up study to estimate seroprevalence of coronavirus disease 2019 in Kobe, Japan
A Doi, K Iwata, H Kuroda, T Hasuike, S Nasu… - Medicine, 2021 - journals.lww.com
We conducted a study to estimate the seroprevalence of coronavirus disease 2019 (COVID-19)
in Kobe, Japan with positive immunoglobulin G (IgG) rate of 3.3%(95% confidence …
in Kobe, Japan with positive immunoglobulin G (IgG) rate of 3.3%(95% confidence …
